Dublin, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The "Analgesics Market By Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The global analgesics market was valued at $26,654.4 million in 2020, and is projected to reach $50,682.6 million by 2030, registering a CAGR of 6.6% during the forecast period 2021-2030. Analgesics, also known as painkillers, are used to treat and reduce pain in the body.
Typically, they are used when the pain is severe and becomes unbearable for the patient. Non-opioids, opioids, and compound analgesics (a combination of both, opioids and non-opioids) are the major analgesic products used globally. The emergence of painkillers is mainly attributed to the increase in acute and chronic diseases, as well as the rise in incidences of cancer globally.
Opioid drugs are the strongest types of painkillers, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.
The global analgesics market is expected to achieve moderate growth in the near future, majorly because of factors, such as increase in cardiovascular disease, cancer, and arthritis and surge in geriatric population. Recurring pain and aches experienced by the ageing population is another factor drives the market growth. In addition, increase in investments in R&D by public and private sectors, with key emphasis on the classes of compounds for formulating new therapeutics, is further expected to drive the analgesics market growth. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are expected to restrain the growth of the global analgesics market.
The analgesics market is segmented on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. By route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Region-wise, it is categorized into North America, Europe, Asia-Pacific, and LAMEA.
A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.
Key Benefits For Stakeholders
- This report provides a detailed - Quantitative analysis of the current market trends and future estimations from 2021 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the analgesics market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter's five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: ANALGESICS MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Non opioids
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Opioids
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Intravenous
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Rectal
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Transdermal
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Topical
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: ANALGESICS MARKET, BY REGION
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 AbbVie Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Bayer AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Eli Lilly and Company
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 endo pharmaceuticals
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Glaxosmithkline plc
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 johnson and johnson md&d
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Pfizer, Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Reckitt Benckiser Group
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Sanofi
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
For more information about this report visit https://www.researchandmarkets.com/r/qmf0s6
Attachment
